Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  bispecific antibody MDX-H210
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-6 of 6 for your search:
Start Over
Phase I/II Pilot Study of Bispecific Antibody 520C9xH22 with GM-CSF for Advanced Malignancies Expressing the HER-2/neu Antigen (Summary Last Modified 12/98)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: GUMC-34594, NCI-V96-0970
Phase IA/IB Study of the Bispecific Antibody 520C9xH22 (MDX-H210) plus Interferon gamma in Metastatic Adenocarcinomas Expressing the HER2/neu Antigen
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MDX-DMS-9318, DMS-9318, NCI-V94-0450
Phase I Study of Bispecific Antibody 520C9xH22 for Advanced Malignancies Expressing the HER-2/neu Antigen
Phase: Phase I
Type: Treatment
Status: Completed
Age: over 18
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: NCI-95-C-0023L, MDX-NCI-95-C-0023L, NCI-MB-360
Phase I Study of the Bispecific Antibody 520C9xH22 for Metastatic Prostate Cancer Expressing the HER2/neu Antigen (Summary Last Modified 06/96)
Phase: Phase I
Type: Treatment
Status: Closed
Age: over 18
Sponsor: Other
Protocol IDs: DMS-9403, NCI-V95-0626
Phase I Study of Bispecific Antibody 520C9xH22 with G-CSF for Relapsed/Refractory Metastatic Cancer that Overexpresses HER2/neu
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MDX-1B-95-2, LAC-USC-1B952, NCI-V95-0658
Start Over